

**EASTERNMED FUNDS VCIC PLC  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2018**

# **EASTERNMED FUNDS VCIC PLC**

---

## **FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018**

<b>CONTENTS</b>	<b>PAGE</b>
Board of Directors and other officers	1
Fund background	2 - 3
Independent auditors' report	4 - 6
Statement of comprehensive income	7
Statement of financial position	8
Statement of net assets attributable to holders of investor shares	9
Statement of cash flows	10
Notes to the financial statements	11 - 33
Schedule of investments - unaudited	34 - 35

# EASTERNMED FUNDS VCIC PLC

---

## BOARD OF DIRECTORS AND OTHER OFFICERS

<b>Board of Directors:</b>	Athanasios J. Martinos Ioannis Papaioannou Andreas Theophanous Stavros A. Karides Maria Panayi Drakos
<b>Secretary:</b>	K and K Secretarial Limited 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
<b>Management Company:</b>	Easternmed Asset Management Services Ltd 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
<b>Fund Administration:</b>	Fiducitrust Services Limited 66 Acropolis Avenue, Acropolis Tower, 2nd floor 2012 Nicosia Cyprus
<b>External Auditors:</b>	KPMG Limited 14 Esperidon Street 1087 Nicosia Cyprus
<b>External Legal Advisers:</b>	Karides & Karides LLC 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
<b>Registered office:</b>	48 Themistokli Dervi Avenue Athienitis Centennial Building, Office 104 1066 Nicosia Cyprus
<b>Depositary:</b>	Bank of Cyprus Public Company Ltd 51 Stasinou Street 1398 Nicosia Cyprus
<b>Registration number:</b>	HE354779

# EASTERNMED FUNDS VCIC PLC

---

## FUND BACKGROUND

### Introduction

Easternmed Funds VCIC Plc (the 'Fund') was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016.

The Fund as an umbrella fund, it may accommodate sub funds relating to different investment portfolios and strategies. Separate classes of shares are issued for each sub fund. The Board of Directors of the Fund may authorise the creation of additional sub funds/share classes in the future

As of 31 December 2018, there was 1 sub fund active, Easternmed Equities Fund (Class A) (the 'Sub-Fund') managed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to Fiducitrust Services Limited (the 'Fund Administrator').

The prospectus of the Fund has been amended and approved by CySEC as of 20 December 2018. The amended investment policy and investment limits allow the fund manager to adapt and invest under different market conditions. In addition, the amended investment policy facilitates better risk management monitoring, since all investment limits are calculated based on the Net Assets Value (the 'NAV').

### Investment objective

The Sub-Fund's objective is to preserve its investors' wealth and to pursue a long-term capital growth strategy subject to moderate volatility with:

- targeted (unlevered) return 3-month Euribor +5% p.a.
- volatility, generally below relevant equity market benchmarks over the investment horizon
- an investment horizon of 10 plus years

### Investment strategy

The Sub-Fund's investment strategy is characterised as long-term, value-oriented and opportunistic. The Sub-Fund invests in highly liquid assets for the long term with emphasis on industries with real rather than intangible assets. While exposures and run comparisons are monitored, there is not at any time strict adherence to commonly used benchmarks. Economic and market risks are closely monitored. In extreme market conditions and in order to safeguard the interests of his stakeholders, the investment manager may decide to liquidate the entire portfolio and invest up to 100% of the Fund's assets in cash and/or cash equivalents.

The strategy focuses on portfolio diversification and risk minimisation. Risk is assessed on individual investments as well as on a portfolio level.

The Sub-Fund is allowed to borrow on a temporary basis up to 10% of its net assets and may use financial derivatives for hedging purposes.

### Investment policy

The Sub-Fund invests more than 50% and up to 100% of its NAV in listed Equities. The Sub-Fund mainly invests in large capitalization (>\$10 billion), well-established European, but also US, companies with a recognizable brand name, solid market share and reputable management. The allocation in European and US equities will vary depending on macroeconomic and financial conditions, attractiveness of each region in terms of companies' valuations, financial risks and on the general investment strategy of the investment manager.

The Sub-Fund may also to a limited extent be allowed to invest opportunistically in less liquid mid and small-cap equities (< \$10 billion) up to 20% of NAV. Although European (but also US) equities will be the main investments of the Sub-Fund, up to 20% of NAV may be allocated to equities of other developed markets while not more than 20% of NAV may be allocated to emerging markets equities.

The Sub-Fund's direct equity investments will concentrate on (a) companies with a solid real asset base in industries such as energy, materials, utilities, industrials, etc., (b) financial companies such as banks and insurance companies and (c) healthcare. Investments in companies with high intangibles relative to their long-terms assets, predominantly IT patents and brand names, will generally be avoided. Specifically, the Sub-Fund may invest up to 35% of NAV in energy, up to 30% of NAV in financials and up to 25% of NAV in each of all other equity sectors.

# EASTERNMED FUNDS VCIC PLC

---

## FUND BACKGROUND

### **Investment policy (continued)**

In order to supplement its direct equity investment activities, the Sub-Fund may further invest a portion of its assets (up to 25% of its net assets) in long-only equity funds (UCITS and Other UCIs) with Assets under Management (the 'AuM') in excess of €500 million.

The Sub-Fund may finally invest less than 50% of its net assets in fixed income and cash (less than 50% of its net assets). Fixed income may also include investments in bond funds (e.g. UCITS, Other UCIs) and money market instruments, which should not exceed 10% of the Sub-Fund's net assets.

The Sub-Fund's bond investments shall focus on developed market corporates as well as emerging markets bonds. Investments in emerging market high yield bonds would be limited to instruments for which the government, including state-owned entities, has an ownership stake of more than 50%.

The Sub-Fund will normally invest in low duration bonds (up to 3 years' maturities) as a means to mitigate credit and interest rate risk. Bonds will generally be deployed as an alternative to cash, preferably with a higher yield, and generally be kept until maturity. Nevertheless, the investment manager may also opt to invest in longer duration bonds in a high interest rate environment.

The Sub-Fund will aim to invest in bonds denominated in the Sub-Fund's base currency i.e. Euro, unless yields available are judged not to be competitive by the investment manager. In such case, as well as taking into consideration currency prospects, the investment manager may also choose to invest in non-EUR denominated bonds, but excluding emerging markets local currency bonds, for currency diversification and/or added yield. The Sub-Fund will not invest in ABS, MBS and convertible bonds (or contingent convertible bonds).

### **Benchmark**

The Sub-Fund is actively run and the returns or investments of the Sub-Fund's portfolio are not compared against a benchmark.



KPMG Limited  
Chartered Accountants  
14 Esperidon Street, 1087 Nicosia, Cyprus  
P.O. Box 21121, 1502 Nicosia, Cyprus  
T: +357 22 209000, F: +357 22 678200

4

## Independent Auditors' report

### TO THE MEMBERS OF EASTERNMED FUNDS VCIC PLC

#### Report on the audit of the financial statements

##### *Opinion*

We have audited the accompanying financial statements of Easternmed Funds VCIC Plc (the "Fund") which are presented on pages 7 to 33 and comprise the statement of financial position as at 31 December 2018, and the statements of comprehensive income, changes in net assets attributable to holders on investors shares and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 31 December 2018, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union ("IFRS-EU") and the requirements of the Cyprus Companies Law, Cap. 113, as amended from time to time (the "Companies Law, Cap. 113").

##### *Basis for opinion*

We conducted our audit in accordance with International Standards on Auditing ("ISAs"). Our responsibilities under those standards are further described in the "Auditors' responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the Code of Ethics for Professional Accountants of the International Ethics Standards Board for Accountants ("IESBA Code"), and the ethical requirements in Cyprus that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Limassol  
P.O. Box 50161, 3601  
T: +357 25 869000  
F: +357 25 363942

Paphos  
P.O. Box 60288, 8101  
T: +357 26 943050  
F: +357 26 943062

P.O. Chryso, na is  
P.O. Box 66014, 8330  
T: +357 26 322098  
F: +357 26 322722

Larnaca  
P.O. Box 40075, 6300  
T: +357 24 200000  
F: +357 24 200200

Paralimni / Aya Napa  
P.O. Box 33200, 5311  
T: +357 23 820080  
F: +357 23 820084

***Responsibilities of the Board of Directors and those charged with governance for the financial statements***

The Board of Directors is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS-EU and the requirements of the Companies Law, Cap. 113, and for such internal control as the Board of Directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless there is an intention to either liquidate the Company or to cease operations, or there is no realistic alternative but to do so.

The Board of Directors and those charged with governance are responsible for overseeing the Company's financial reporting process.

***Auditors' responsibilities for the audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves true and fair view.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Other matter**

This report, including the opinion, has been prepared for and only for the Company's members as a body in accordance with Section 69 Law, L.53(I)/2017, as amended from time to time, and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whose knowledge this report may come to.



Maria A. Karantoni, FCA  
Certified Public Accountant and Registered Auditor  
for and on behalf of

KPMG Limited  
Certified Public Accountants and Registered Auditors  
14 Esperidon Street  
1087 Nicosia  
Cyprus

17 April 2019



## EASTERNMED FUNDS VCIC PLC

### STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2018

	Note	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
<b>Revenue</b>			
Dividend income		2.903.798	1.569.538
Interest income	5	105.173	235.693
Net realised gains on financial assets at fair value through profit or loss	7	687.707	246.279
Net unrealised (losses)/gains on financial assets at fair value through profit or loss	6,12	(11.714.348)	2.115.909
Net foreign currency gains/(losses)		25.527	(40.822)
Other operating income		43.498	-
<b>Total revenue</b>		<b>(7.948.645)</b>	<b>4.126.597</b>
<b>Operating expenses</b>			
Management fees		(422.870)	(253.186)
Depositary fees		(44.067)	(26.427)
Administration fees		(42.287)	(25.301)
Directors' fees		(9.570)	(9.570)
Transaction costs		(73.991)	(103.844)
Auditors' remuneration		(9.342)	(8.449)
Secretarial fees		(4.760)	(5.772)
Professional fees		(2.550)	(44)
Licences and annual contributions		(1.800)	(1.800)
Other expenses		(835)	(654)
<b>Total operating expenses</b>		<b>(612.072)</b>	<b>(435.047)</b>
<b>Operating (loss)/profit before finance costs</b>		<b>(8.560.717)</b>	<b>3.691.550</b>
Net finance costs	8	(151)	(2)
<b>(Decrease)/increase in net assets attributable to holders of investor shares before tax</b>		<b>(8.560.868)</b>	<b>3.691.548</b>
Tax	9	(171.696)	(82.668)
<b>(Decrease)/increase in net assets attributable to holders of investor shares for the year</b>		<b>(8.732.564)</b>	<b>3.608.880</b>

The notes on pages 11 to 33 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## STATEMENT OF FINANCIAL POSITION AT 31 DECEMBER 2018

	Note	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
<b>ASSETS</b>			
Financial assets at fair value through profit or loss	12	78.132.877	67.742.900
Cash and cash equivalents	13	6.695.179	693.314
Other receivables	11	70.253	180.047
<b>Total assets</b>		<b>84.898.309</b>	<b>68.616.261</b>
<b>LIABILITIES</b>			
Other payables	15	73.658	56.274
Current tax liabilities	16	34	2.422
		<b>73.692</b>	<b>58.696</b>
<b>Total liabilities (excluding net assets attributable to holders of investor shares)</b>		<b>73.692</b>	<b>58.696</b>
<b>Net assets attributable to holders of investor shares</b>		<b>84.824.617</b>	<b>68.557.565</b>
		<b>84.824.617</b>	<b>68.557.565</b>

On 17 April 2019 the Board of Directors of Easternmed Funds VCIC Plc authorised these financial statements for issue.

  
Athanasios J. Martinos  
Director

  
Ioannis Papaioannou  
Director

The notes on pages 11 to 33 form an integral part of these financial statements.

## EASTERNMED FUNDS VCIC PLC

### STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF INVESTOR SHARES FOR THE YEAR ENDED 31 DECEMBER 2018

	Note	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Balance at 1 January		68.557.565	39.948.685
(Decrease)/increase in net assets attributable to holders of investor shares	14	<u>(8.732.564)</u>	<u>3.608.880</u>
<b>Contributions and redemptions by holders of investor shares:</b>			
Subscription for Class A investor shares during the year		<u>24.999.616</u>	<u>25.000.000</u>
<b>Total contributions and redemptions by holders of investor shares</b>		<u>24.999.616</u>	<u>25.000.000</u>
<b>Balance at 31 December</b>		<u><b>84.824.617</b></u>	<u><b>68.557.565</b></u>

The notes on pages 11 to 33 form an integral part of these financial statements.

## EASTERNMED FUNDS VCIC PLC

### STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2018

	Note	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
(Decrease)/increase in net assets attributable to holders of investor shares before tax		(8.560.868)	3.691.548
Adjustments for:			
Net realised gains on financial assets at fair value through profit or loss	7	(687.707)	(246.279)
Net unrealised losses/(gains) on financial assets at fair value through profit or loss	6	11.714.348	(2.115.909)
Net foreign currency (gains)/losses		(25.527)	40.812
Dividend income		(2.903.798)	(1.569.538)
Interest income	5	(105.173)	(235.693)
Other operating income		(43.498)	-
		(612.223)	(435.059)
<b>Changes in working capital:</b>			
Increase in balances with brokers		-	(1.747.327)
Increase in other payables		17.384	27.436
<b>Cash used in operations</b>		(594.839)	(2.154.950)
Interest received		34.379	185.367
Dividends received		2.833.545	1.389.491
Proceeds from sale of financial assets at fair value through profit or loss		7.839.856	5.635.012
Payments for acquisition of financial assets at fair value through profit or loss		(28.962.135)	(39.593.778)
Tax paid		(3.526)	(4.187)
Withholding tax paid		(170.558)	(77.570)
<b>Net cash used in operating activities</b>		(19.023.278)	(34.620.615)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of investor shares	14	24.999.616	25.000.000
<b>Net cash generated from financing activities</b>		24.999.616	25.000.000
<b>Net increase/(decrease) in cash and cash equivalents</b>		5.976.338	(9.620.615)
Cash and cash equivalents at beginning of the year		693.314	10.354.741
Effect of exchange rate fluctuations on cash held		25.527	(40.812)
<b>Cash and cash equivalents at end of the year</b>	13	6.695.179	693.314

The notes on pages 11 to 33 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 1. Incorporation and principal activities

#### Country of incorporation

Easternmed Funds VCIC Plc (the 'Fund') was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016. Its registered office is at 48 Themistokli Dervi Avenue, Athienitis Centennial Building, Office 104, 1066 Nicosia, Cyprus.

The Fund as an umbrella investment company comprises various sub-funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub-funds. The Board of Directors of the Fund may authorise the creation of additional sub-funds/share classes in the future. As of 31 December 2018, there was one sub-fund active, namely the Easternmed Equities Fund Class A (the 'Sub-Fund').

The Fund is primarily involved in investing in a highly diversified portfolio of equity securities issued by companies listed on major European stock exchanges and on the New York Stock Exchange (NYSE), investment funds and corporate debt securities, with the objective of providing shareholders with long-term capital growth subject to moderate volatility.

The Fund's management is performed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to Fiducitrust Services Limited (the 'Fund Administrator').

### 2. Significant accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented in these financial statements unless otherwise stated.

#### Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards (the 'IFRSs') as adopted by the European Union (the 'EU') and the requirements of the Cyprus Companies Law, Cap.113. The financial statements have been prepared under the historical cost convention except for financial assets and financial liabilities at fair value through profit or loss.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires the Board of Directors to exercise its judgement in the process of applying the Fund's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in Note 4.

This is the first set of the Fund's annual financial statements in which IFRS 9 "Financial Instruments" has been applied.

#### Adoption of new and revised IFRSs

During the current year the Fund adopted all the new and revised IFRSs as adopted by the EU that are relevant to its operations and are effective for accounting periods beginning on 1 January 2018.

At the date of approval of these financial statements, standards and interpretations were issued by the International Accounting Standards Board (the 'IASB') which were not yet effective. Some of them were adopted by the EU and others not yet. The Board of Directors expects that the adoption of these accounting standards in future periods will not have a material effect on the financial statements of the Fund.

The Fund has initially applied IFRS 9 from 1 January 2018. A number of other new standards are also effective from 1 January 2018 but they do not have a material effect on the Fund's financial statements. As permitted by the transition provisions of IFRS 9, comparative information throughout these financial statements has not generally been restated to reflect the requirements of the standard.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 2. Significant accounting policies (continued)

#### Adoption of new and revised IFRSs (continued)

IFRS 9 sets out requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items. This standard replaces IAS 39 "Financial Instruments: Recognition and Measurement". As a result of the adoption of IFRS 9, the Fund has adopted consequential amendments to IAS 1 "Presentation of Financial Statements", which require:

- impairment of financial assets to be presented in a separate line item in the statement of comprehensive income. Under IAS 39, impairment was recognised when losses were incurred. The Fund did not previously report any incurred losses; and
- separate presentation in the statement of comprehensive income of interest revenue calculated using the effective interest method. Previously, the Fund disclosed this amount in the notes to the financial statements.

Additionally, the Fund has adopted consequential amendments to IFRS 7 "Financial Instruments: Disclosures", which are applied to disclosures about 2018 but have not generally been applied to comparative information.

The adoption of IFRS 9 had no material impact on the net assets attributable to holders of investor shares.

#### (i) Classification and measurement of financial assets and financial liabilities

IFRS 9 contains three principal classification categories for financial assets: measured at amortised cost, fair value through other comprehensive income (the 'FVOCI') and fair value through profit or loss (the 'FVTPL'). The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. IFRS 9 eliminates the previous IAS 39 categories of held to maturity, loans and receivables and available for sale. Under IFRS 9, derivatives embedded in contracts where the host is a financial asset in the scope of the standard are never separated. Instead, the hybrid financial instrument as a whole is assessed for classification.

IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities. The adoption of IFRS 9 has not had a significant effect on the Fund's accounting policies related to financial liabilities and derivative financial instruments.

The following table and the accompanying notes below explain the original measurement categories under IAS 39 and the new measurement categories under IFRS 9 for each class of the Fund's financial assets and financial liabilities as at 1 January 2018. The effect of adopting IFRS 9 on the carrying amounts of financial assets and financial liabilities at 1 January 2018 relates solely to the new impairment requirements.

	Original classification under IAS 39	New classification under IFRS 9	Original carrying amount under IAS 39 €	New carrying amount under IFRS 9 €
<b>Financial assets</b>				
Cash and bank balances	Loans and receivables	Amortised cost	693.314	693.314
Other receivables	Loans and receivables	Amortised cost	180.047	180.047
Equity securities	Designated as at FVTPL	Mandatorily at FVTPL	61.731.431	61.731.431
Listed open-ended investment funds	Designated as at FVTPL	Mandatorily at FVTPL	986.948	986.948
Unlisted open-ended investment funds	Designated as at FVTPL	Mandatorily at FVTPL	2.082.353	2.082.353
Debt securities	Designated as at FVTPL	Mandatorily at FVTPL	2.942.168	2.942.168
<b>Total financial assets</b>			<b>68.616.261</b>	<b>68.616.261</b>
<b>Financial liabilities</b>				
Other payables	Amortised cost	Amortised cost	56.274	56.274
Current tax liabilities	Amortised cost	Amortised cost	2.422	2.422
Net assets attributable to holders of investor shares	Amortised cost	Amortised cost	68.557.565	68.557.565
<b>Total financial liabilities</b>			<b>68.616.261</b>	<b>68.616.261</b>

# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 2. Significant accounting policies (continued)

#### Adoption of new and revised IFRSs (continued)

Under IAS 39, there were financial assets designated at fair value through profit or loss because they were managed on a fair value basis and their performance was monitored on this basis. On adoption of IFRS 9 these securities are mandatorily classified as fair value through profit or loss.

#### (ii) Impairment of financial assets

IFRS 9 replaces the "incurred loss" model in IAS 39 with an "expected credit loss" (ECL) model. The new impairment model applies to financial assets measured at amortised cost and debt investments at FVOCI, but not to investments in equity instruments. Under IFRS 9, credit losses are recognised earlier than under IAS 39.

The Fund has determined that the application of IFRS 9's impairment requirements at 1 January 2018 has not resulted in any impairment on financial assets.

#### (iii) Transition

Changes in accounting policies resulting from the adoption of IFRS 9 have been applied retrospectively, except as described below.

- Comparative periods have not generally been restated. Differences in the carrying amounts of financial assets resulting from the adoption of IFRS 9 are recognised in net assets attributable to holders of redeemable shares as at 1 January 2018. Accordingly, the information presented for 2017 does not reflect the requirements of IFRS 9, but rather those of IAS 39.
- The following assessments have been made on the basis of the facts and circumstances that existed at the date of initial application.
  - The determination of the business model within which a financial asset is held.
  - The revocation of previous designations of certain financial assets as measured at FVTPL.

#### Revenue recognition

- **Net realised/unrealised gain on financial assets at fair value through profit or loss**

Net realised/unrealised gain from financial assets at fair value through profit or loss includes all realised and unrealised fair value changes, foreign exchange differences but excludes interest and dividend income.

- **Interest income**

Interest on debt securities at fair value through profit or loss is accrued on a time-proportionate basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition. Interest income is recognised gross of withholding tax, if any. Also, interest income from cash and cash equivalents is recognised on a time-proportionate basis using the effective interest method.

- **Dividend income**

Dividend income from investments is recognised when the shareholders' rights to receive payment have been established, normally declaration date for final dividends and payment date for interim dividends.

# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 2. Significant accounting policies (continued)

#### Dividends to holders of investor shares

Dividends to holders of investor shares are recognised in the statement of comprehensive income as finance costs when they are authorised and are no longer at the discretion of the Fund. Dividends are subject to the special defense levy applicable to natural persons, whereas legal entities or natural persons who are not tax residents of Cyprus are exempted from the levy.

#### Finance costs

Interest expense and other borrowing costs are charged to profit or loss as incurred.

#### Foreign currency translation

(1) **Functional and presentation currency**

Items included in the Fund's financial statements are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Euro (€), which is the Fund's functional and presentation currency.

(2) **Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary items and non-monetary assets and liabilities that are measured at fair value in a foreign currency are included in profit or loss. Foreign exchange gains and losses on financial assets and financial liabilities at fair value through profit or loss are recognised together with other changes in the fair value. Net foreign exchange gains/(losses) on non-monetary and monetary financial assets and liabilities other than those classified as at fair value through profit or loss are included in the line item net foreign currency gains/(losses) in the statement of comprehensive income.

#### Tax

Current tax liabilities and assets are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates and laws that have been enacted, or substantively enacted, by the reporting date.

Income from investments held by the Fund may be subject to withholding taxes in jurisdictions other than that of the Fund's as imposed by the country of origin. Withholding taxes, if any, are shown in a separate line item in the statement of comprehensive income.

#### Financial assets and financial liabilities at fair value through profit or loss

(1) Classification

The portfolio of financial assets and financial liabilities is managed and performance is evaluated on a fair value basis. The Fund is primarily focused on fair value information and uses that information to assess the assets' performance and to make decisions. The Fund has not taken the option to irrevocably designate any equity securities as fair value through other comprehensive income. The contractual cash flows of the Fund's debt securities are solely principal and interest, however, these securities are neither held for the purpose of collecting contractual cash flows nor held both for collecting contractual cash flows and for sale. The collection of contractual cash flows is only incidental to achieving the Fund's business model's objective. Consequently, all investments are measured at fair value through profit or loss.

The Fund's policy requires the Board of Directors to evaluate the information about these financial assets and liabilities on a fair value basis together with other related financial information.



# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 2. Significant accounting policies (continued)

#### Financial assets and financial liabilities at fair value through profit or loss (continued)

##### *(2) Recognition, derecognition and measurement*

Financial assets and liabilities at fair value through profit or loss are recognised when the Fund becomes party to the contractual provisions of the instrument. Recognition takes place on the trade date where the purchase or sale of an investment is under a contract whose terms require delivery of the investment within the time frame established by the market concerned. Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed as incurred in the statement of comprehensive income.

Financial assets are derecognised when the contractual rights to the cash flows from the investments have expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities at fair value through profit or loss are derecognised when the obligation specified in the contract is discharged, cancelled or expired. Realised gains and realised losses on derecognition are determined using the weighted average cost method and are included in profit or loss for the period in which they arise.

At initial recognition financial assets and liabilities are measured at fair value. Transaction costs on financial assets and liabilities at fair value through profit or loss are expensed as incurred in the statement of comprehensive income.

Subsequent to initial recognition, financial assets and liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in their fair value are included in the statement of comprehensive income for the period in which they arise. Interest earned on financial assets at fair value through profit or loss and interest expense on the financial liabilities at fair value through profit or loss are disclosed in a separate line item in the statement of comprehensive income.

Dividend income from financial assets at fair value through profit or loss is recognised in the statement of comprehensive income within dividend income when the Fund's right to receive payments is established. Interest on debt securities at fair value through profit or loss is recognised in the statement of comprehensive income within interest income based on the effective interest rate. Dividend expense on short sales of equity securities is included within other net changes in fair value on financial assets and financial liabilities at fair value through profit or loss.

Dividend expense on equity securities sold short are included in the net gain or loss arising on financial assets and financial liabilities measured at fair value through profit or loss.

#### **Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short term investments with original maturities of three months or less, bank overdrafts and money market funds with daily liquidity and all highly liquid financial instruments that mature within three months of being purchased.

#### **Offsetting financial instruments**

Financial assets and financial liabilities are offset and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Income and expenses are presented on a net basis for gains and losses from financial instruments at fair value through profit or loss and foreign exchange gains and losses.

#### **Provisions**

Provisions are recognised when the Fund has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made. Where the Fund expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain.

# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 2. Significant accounting policies (continued)

#### Expenses

All expenses are recognised in the statement of comprehensive income on an accrual basis.

#### Investor shares and net assets attributable to holders of investor shares

The Fund has two classes of investor shares in issue: Class A and Class B. Both are the most subordinate classes of financial instruments in the Fund and rank *pari passu* in all material respects and have the same terms and conditions, with the exemption of the subscription, redemption and management fee. As the share classes do not have identical features, these instruments do not meet the definition of puttable financial instruments to be classified as equity in accordance with IAS 32.

Investor shares can be put back into the Fund at any time for cash equal to a proportionate share of the Fund's Net Asset Value ('NAV') attributable to the share class. The investor shares are classified as financial liabilities and are measured at the redemption amounts.

Investor shares are issued and redeemed at the holder's option at prices based on the Fund's net asset value per share at the time of issue or redemption. The Fund's net asset value per share is calculated by dividing the net assets attributable to the holders of each class of investor shares with the total number of outstanding investor shares for each respective class. In accordance with the provisions of the Fund's regulations, investment positions are valued based on the last traded market price for the purpose of determining the net asset value per share for subscriptions and redemptions.

Proposed distributions to holders of investor shares are recognised in the statement of comprehensive income when they are appropriately authorised and no longer at the discretion of the Fund. This typically occurs when proposed distribution is ratified at the Annual General Meeting. The distribution on the investor shares is recognised as a finance cost in the statement of comprehensive income.

Income not distributed is included in net assets attributable to holders of investor shares. Movements in net assets attributable to holders of investor shares are recognised in the statement of comprehensive income as finance costs.

#### Related party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Related party transactions are transfers of resources or obligations between related parties, regardless of whether a price is charged.

#### Events after the reporting period

Assets and liabilities are adjusted for events that occurred during the period from the reporting date to the date of approval of the financial statements by the Board of Directors, when these events provide additional information for the valuation of amounts relating to events existing at the reporting date or imply that the going concern concept in relation to part of the whole of the Fund is not appropriate.

#### Comparatives

Where necessary, comparative figures have been adjusted to conform to changes in presentation in the current year.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management

#### Financial risk factors

The Fund is exposed to credit risk, liquidity risk, market risk and operational risk arising from the financial instruments it holds. The risk management policies employed by the Fund to manage these risks are discussed below:

#### 3.1 Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Fund. The Fund is exposed to credit risk from its operating activities, primarily from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

At reporting date, the main concentration to which the Fund is exposed arises from the Fund's investments in debt securities. The Fund is also exposed to counterparty credit risk on cash and cash equivalents and other receivable balances. It is the opinion of the Board of Directors that the carrying amounts of these financial assets represent the maximum credit risk exposure at the reporting date.

The Board of Directors has a documented policy in place of spreading the aggregate value of transactions concluded amongst approved counterparties with an appropriate credit quality. The Fund's exposure and the credit ratings of its counterparties are continuously monitored by management. The following table summarises the credit quality of the debt instruments in the portfolio, as rated by well-known rating agencies such as Standard & Poor's approved by the Board of Directors, or in the case of an unrated debt instrument, the rating as assigned by the Board of Directors using an approach consistent with that of the respective rating agencies.

#### 3.1.1 Analysis of credit quality on financial assets

##### Cash and cash equivalents

The Fund's cash and cash equivalents are held mainly with Bank of Cyprus Public Company Ltd, which is rated Caa1 based on Moody's ratings. The investment manager monitors the financial position of Bank of Cyprus Public Company Ltd on a monthly basis.

##### Investments in debt securities

At 31 December, the Fund invested in corporate debt securities with the following credit quality. The ratings are based on Standard & Poor's ratings.

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €	Easternmed Equities Fund Class A 2018 %	Easternmed Equities Fund Class A 2017 %
BBB+	867.087	479.188	17,60%	16,29%
BBB	1.361.331	-	27,64%	-
BBB-	-	154.089	-	5,24%
BB+	2.280.308	845.108	46,29%	28,72%
BB-	-	1.041.185	-	35,39%
Unrated	417.368	422.598	8,47%	14,36%
<b>Total</b>	<b>4.926.094</b>	<b>2.942.168</b>	<b>100,00%</b>	<b>100,00%</b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.1 Credit risk (continued)

##### 3.1.2 Concentration of credit risk of financial assets

The investment manager reviews the credit concentration of debt securities held based on counterparties and industries.

As at the reporting date, the Fund's debt securities exposures were concentrated in the following industries.

	Easternmed Equities Fund Class A 2018 %	Easternmed Equities Fund Class A 2017 %
Communications	-	35,39%
Consumer Discretionary	-	16,29%
Energy	17,68%	14,36%
Financials	82,32%	33,96%
	<u>100,00%</u>	<u>100,00%</u>

#### 3.2 Liquidity risk

Liquidity risk is the risk that the Fund may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can only do so on terms that are materially disadvantageous.

The Fund is exposed to the daily settlement of cash redemptions of investor shares. The Fund's investor shares are redeemable at the shareholders' option at any time for cash equal to a proportionate share of the Fund's NAV. The Fund is therefore potentially exposed to redemptions by its shareholders.

The Fund invests primarily in marketable securities and other financial instruments, which under normal market conditions are readily convertible to cash. The Fund's marketable securities and other financial instruments are considered readily realisable, as the majority are listed on the New York and European stock exchanges. Its policy is therefore to invest the majority of its assets in investments that are traded in an active market and can be readily disposed. Only a limited proportion of its assets in investments are not actively traded on a stock exchange. In addition, the Fund's policy is to maintain sufficient cash and cash equivalents to meet normal operating requirements and expected redemption requests.

The Fund's financial assets include investments in unlisted open-ended investment funds which may not be readily realisable due to lock-up periods, extended withdrawal, notice or settlement periods or in extraordinary cases periods in which redemptions are suspended due to adverse market conditions.

It is the Fund's policy that the investment manager and the Board of Directors monitor the Fund's liquidity position on a weekly basis.

The following tables detail the Fund's remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Fund can be required to pay. The table includes both interest and principal cash flows.

31 December 2018	Carrying amounts €	Contractual cash flows €	3 months or less €	3-12 months €
Accruals	73.076	73.076	73.076	-
Payables to related parties	582	582	-	582
Net assets attributable to holders of investor shares	<u>84.824.617</u>	<u>84.824.617</u>	<u>84.824.617</u>	<u>-</u>
	<u>84.898.275</u>	<u>84.898.275</u>	<u>84.897.693</u>	<u>582</u>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.2 Liquidity risk (continued)

31 December 2017	Carrying amounts €	Contractual cash flows €	3 months or less €	3-12 months €
Accruals	56.274	56.274	56.274	-
Net assets attributable to holders of investor shares	68.557.565	68.557.565	68.557.565	-
	<u>68.613.839</u>	<u>68.613.839</u>	<u>68.613.839</u>	<u>-</u>

The tables above show the undiscounted cash flows of the Fund's financial liabilities on the basis of their earliest possible contractual maturity. The Fund's expected cash flows on these instruments (other than net assets attributable to the holders of investor shares) do not vary significantly from this analysis. For net assets attributable to the holders of investor shares, the Fund has a contractual obligation to redeem within four working days from the date the application for the redemption of the investor shares is submitted.

#### 3.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Fund's income or the value of its holdings of financial instruments.

The Fund's market risk is managed on a monthly basis by the investment manager in accordance with the policies and procedures in place and through diversification of the investment portfolio. The Fund's market positions are monitored on a quarterly basis by the Board of Directors.

##### 3.3.1 Price risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting similar financial instruments traded in the market.

The Fund is exposed to financial instruments price risk because of investments held by the Fund and classified on the statement of financial position at fair value through profit or loss. The Fund is not exposed to commodity price risk.

The investment manager manages the Fund's price risk on a monthly basis and through diversification of the investment portfolio. The Fund's overall market positions are monitored on a quarterly basis by the Board of Directors.

##### Sensitivity analysis

A five percent change in prices is the sensitivity rate used when reporting price risk internally to key management personnel and representing management's assessment of a reasonably possible change in prices.

At 31 December 2018, if prices had been five percent higher with all other variables held constant, the increase in net assets attributable to holders of investor shares for the year would have been €4.241.233 higher, arising due to the increase in the fair value of financial assets at fair value through profit or loss by €4.241.233.

If prices had been five percent lower with all other variables held constant the decrease in net assets attributable to holders of investor shares for the year would have been €4.241.233 lower, arising mainly due to the decrease in the fair value of financial assets at fair value through profit or loss by €4.241.233.

##### 3.3.2 Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.3. Market risk (continued)

##### 3.3.2 Interest rate risk (continued)

The Fund is exposed to interest rate risk as it invests in listed debt securities bearing interest at both fixed and floating interest rates. Other financial assets exposed to interest rate risk include cash and bank balances which are invested at short term interest rates. The investment manager manages the Fund's exposure to interest rate risk on a monthly basis in accordance with the Fund's investment objectives and policies. The Fund's overall exposure to interest rate risk is monitored on a quarterly basis by the board of directors.

The following table details the Fund's exposure to interest rate risk as at 31 December 2018 by the earlier of contractual maturities or re-pricing:

31 December 2018

	Non- interest bearing €	Less than 1 month €	1-3 months €	3 months to 1 year €	More than 1 year €	Total €
<b>Assets</b>						
Non-interest bearing	73.277.036	-	-	-	-	73.277.036
Floating interest rate debt securities	-	-	-	-	-	-
Fixed interest rate debt securities	-	32.150	-	2.265.295	2.628.649	4.926.094
Cash and bank balances	-	6.695.179	-	-	-	6.695.179
<b>Total assets</b>	<b>73.277.036</b>	<b>6.727.329</b>	<b>-</b>	<b>2.265.295</b>	<b>2.628.649</b>	<b>84.898.309</b>
<b>Liabilities</b>						
Non-interest bearing	73.692	-	-	-	-	73.692
Net assets attributable to holders of investor shares	84.824.617	-	-	-	-	84.824.617
<b>Total liabilities</b>	<b>84.898.309</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>84.898.309</b>

31 December 2017

	Non- interest bearing €	Less than 1 month €	1-3 months €	3 months to 1 year €	More than 1 year €	Total €
<b>Assets</b>						
Non-interest bearing	64.980.779	-	-	-	-	64.980.779
Floating interest rate debt securities	-	-	154.089	-	-	154.089
Fixed interest rate debt securities	-	-	1.059.571	1.316.068	412.440	2.788.079
Cash and bank balances	-	693.314	-	-	-	693.314
<b>Total assets</b>	<b>64.980.779</b>	<b>693.314</b>	<b>1.213.660</b>	<b>1.316.068</b>	<b>412.440</b>	<b>68.616.261</b>
<b>Liabilities</b>						
Non-interest bearing	58.696	-	-	-	-	58.696
Net assets attributable to holders of investor shares	68.557.565	-	-	-	-	68.557.565
<b>Total liabilities</b>	<b>68.616.261</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>68.616.261</b>

In accordance with the Fund's policies, the investment manager monitors the Fund's overall interest sensitivity on a monthly basis and the Board of Directors reviews it on a quarterly basis.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.3. Market risk (continued)

##### 3.3.3 Currency risk

Currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Fund invests in securities and other investments that are denominated in currencies other than the Euro. Accordingly, the value of the Fund's assets may be affected favorably or unfavorably by fluctuations in currency rates and therefore the Fund is subject to foreign exchange risks. The Fund undertakes certain transactions denominated in foreign currencies and hence is exposed to the effects of exchange rate fluctuations. The Fund's management monitors the exchange rate fluctuations on a continuous basis and acts accordingly.

The carrying amounts of the Fund's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

	Liabilities		Assets	
	Easternmed Equities Fund Class A 2018	Easternmed Equities Fund Class A 2017	Easternmed Equities Fund Class A 2018	Easternmed Equities Fund Class A 2017
	€	€	€	€
United States Dollars	-	-	14.790.490	13.252.710
British Pounds	-	-	9.617.344	9.071.526
Swiss Franc	-	-	6.116.672	2.903.264
Swedish Krona	-	-	1.200.546	864.331
Norwegian Krone	-	-	283.709	572.104
Danish Krone	-	-	1.337.464	763.811
Canadian Dollars	-	-	2.035.947	-
	-	-	<u>35.382.172</u>	<u>27.427.746</u>

##### Sensitivity analysis

A 10% strengthening of the Euro against the following currencies at 31 December 2018 would have increased (decreased) net assets attributable to holders of investor shares by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. For a 10% weakening of the Euro against the relevant currency, there would be an equal and opposite impact on net assets attributable to holders of investor shares.

	Net Assets	
	Easternmed Equities Fund Class A 2018	Easternmed Equities Fund Class A 2017
	€	€
United States Dollars	1.479.049	1.325.271
British Pounds	961.734	907.153
Swiss Franc	611.667	290.326
Swedish Krona	120.055	86.433
Norwegian Krone	28.371	57.210
Danish Krone	133.746	76.381
Canadian Dollars	203.595	-
	<u>3.538.217</u>	<u>2.742.774</u>

# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.4 Operational risk

Operational risk is the risk of direct or indirect loss arising from a wide variety of causes associated with the processes, technology and infrastructure supporting the Fund's activities with financial instruments, either internally within the Fund or externally at the Fund's service providers, and from external factors other than credit, market and liquidity risks such as those arising from legal and regulatory requirements and generally accepted standards of investment management behaviour.

The Fund's objective is to manage operational risk so as to balance the limiting of financial losses and damage to its reputation with achieving its investment objective of generating returns to investors.

The primary responsibility for the development and implementation of controls over operational risk rests with the Board of Directors. This responsibility is supported by the development of overall standards for the management of operational risk, which encompasses the controls and processes at the service providers and the establishment of service levels with the service providers, in the following areas:

- documentation of controls and procedures
- requirements for:
  - appropriate segregation of duties between various functions, roles and responsibilities
  - reconciliation and monitoring of transactions
  - periodic assessment of operational risk faced
- the adequacy of controls and procedures to address the risks identified
- compliance with regulatory and other legal requirements
- development of contingency plans
- training and professional development
- ethical and business standards
- risk mitigation, including insurance if this is effective

The directors' assessment of the adequacy of the controls and processes in place at the service providers with respect to operational risk is carried out via regular discussions with the service providers and a review of the service providers' reports on internal controls, if any are available.

Substantially all of the assets of the Fund are held by Bank of Cyprus Public Company Ltd (the 'Depositary'). The bankruptcy or insolvency of the Fund's Depositary may cause the Fund's rights with respect to the securities held by the Depositary to be limited. The investment manager monitors the credit ratings and capital adequacy of its Depositary on a monthly basis, and reviews the findings documented in the reports on the internal controls annually.



# EASTERNMED FUNDS VCIC PLC

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

#### 3.5 Fair value estimation

The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and securities) are based on quoted market prices at the close of trading on the year-end date. The quoted market price used for financial assets and financial liabilities of the Fund is the last traded price provided such price is within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the points within the bid-ask spread that are most representative of the fair value. The price used is not adjusted for transaction costs.

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.

The fair value of financial assets and liabilities that are not traded in an active market is determined by using valuation techniques. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each year-end date. Valuation techniques used include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants, making the maximum use of observable inputs and relying as little as possible on unobservable inputs.

For instruments for which there is no active market, the Fund may also use internally developed models, which are usually based on valuation methods and techniques generally recognised as standard within the industry. Some of the inputs to these models may not be market observable and are therefore estimated based on assumptions.

The output of a model is always an estimate or approximation of a value that cannot be determined with certainty, and valuation techniques employed may not fully reflect all factors relevant to the positions the Fund holds. Valuations are therefore adjusted, where appropriate, to allow for additional factors including model risk, liquidity risk and counterparty risk.

#### Fair value measurements recognised in statement of financial position

The level of the fair value hierarchy of an instrument is determined considering the inputs that are significant to the entire measurement of such instrument and the level of the fair value hierarchy within which those inputs are categorised.

The fair value hierarchy categorises inputs into the following levels:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Fund. The Fund considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Unobservable inputs are used to measure fair value to the extent that relevant observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. However, the fair value measurement objective remains the same, i.e., an exit price at the measurement date from the perspective of a market participant that holds the asset or owes the liability. Therefore, unobservable inputs reflect the assumptions that market participants would use when pricing the asset or liability, including assumptions about risk.

## EASTERNMED FUNDS VCIC PLC

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

#### 3. Financial risk management (continued)

The following table provides an analysis of financial instruments measured at fair value at the year end date by the level in the fair value hierarchy into which the fair value measurement is categorised. All these fair value measurements are recurring.

31 December 2018	Level 1 €	Level 2 €	Level 3 €	Total €
<b>Financial assets mandatorily at fair value through profit or loss at inception:</b>				
<b>Equity securities</b>				
Financials	11,516,266	-	-	11,516,266
Materials	13,309,791	-	-	13,309,791
Energy	19,943,402	-	-	19,943,402
Utilities	8,167,511	-	-	8,167,511
Consumer Staples	1,434,971	-	-	1,434,971
Technology	2,242,146	-	-	2,242,146
Industrials	5,503,006	-	-	5,503,006
Health Care	4,546,737	-	-	4,546,737
Communications	1,802,837	-	-	1,802,837
Consumer Discretionary	459,550	-	-	459,550
	<u>68,926,217</u>	<u>-</u>	<u>-</u>	<u>68,926,217</u>
<b>Unlisted open-ended investment funds</b>				
Health Care	-	4,280,566	-	4,280,566
	<u>-</u>	<u>4,280,566</u>	<u>-</u>	<u>4,280,566</u>
<b>Debt securities</b>				
Energy	871,083	-	-	871,083
Financials	4,055,011	-	-	4,055,011
	<u>4,926,094</u>	<u>-</u>	<u>-</u>	<u>4,926,094</u>
<b>Total</b>	<b><u>73,852,311</u></b>	<b><u>4,280,566</u></b>	<b><u>-</u></b>	<b><u>78,132,877</u></b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 3. Financial risk management (continued)

31 December 2017	Level 1 €	Level 2 €	Level 3 €	Total €
Financial assets designated at fair value through profit or loss at inception:				
<b>Equity securities</b>				
Financials	11.882.222	-	-	11.882.222
Materials	11.871.507	-	-	11.871.507
Energy	16.089.368	-	-	16.089.368
Utilities	6.965.638	-	-	6.965.638
Consumer Staples	1.525.175	-	-	1.525.175
Technology	1.556.561	-	-	1.556.561
Industrials	6.576.888	-	-	6.576.888
Health Care	1.971.849	-	-	1.971.849
Communications	1.231.823	-	-	1.231.823
Consumer Discretionary	2.060.400	-	-	2.060.400
	<u>61.731.431</u>	<u>-</u>	<u>-</u>	<u>61.731.431</u>
<b>Listed open-ended investment funds</b>				
Health Care	986.948	-	-	986.948
	<u>986.948</u>	<u>-</u>	<u>-</u>	<u>986.948</u>
<b>Unlisted open-ended investment funds</b>				
Health Care	-	2.082.353	-	2.082.353
	<u>-</u>	<u>2.082.353</u>	<u>-</u>	<u>2.082.353</u>
<b>Debt securities</b>				
Energy	422.598	-	-	422.598
Financials	999.197	-	-	999.197
Communications	1.041.185	-	-	1.041.185
Consumer Discretionary	479.188	-	-	479.188
	<u>2.942.168</u>	<u>-</u>	<u>-</u>	<u>2.942.168</u>
<b>Total</b>	<u>65.660.547</u>	<u>2.082.353</u>	<u>-</u>	<u>67.742.900</u>

Valuation techniques and the inputs used for the fair value measurements categorised within Level 2 of the fair value hierarchy is given below:

#### Unlisted open-ended investment funds

The Fund invests in managed funds, which are not quoted in an active market and which may be subject to restrictions on redemptions such as lock up periods, redemption gates and side pockets. The Fund's investment manager considers the valuation techniques and inputs used in valuing these funds as part of its due diligence prior to investing, to ensure they are reasonable and appropriate and therefore the NAV of these funds may be used as an input into measuring their fair value. In measuring this fair value, the NAV of the funds is adjusted, as necessary, to reflect restrictions on redemptions, and other specific factors of the fund and fund manager. In measuring fair value, consideration is also given to any transactions in the shares of the fund. Depending on the nature and level of adjustments needed to the NAV and the level of trading in the fund, the Fund classifies these funds as either Level 2 or Level 3.

There were no transfers between Level 1 and Level 2 in the year.

### 4. Critical accounting estimates and judgements

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and requires Management to exercise its judgement in the process of applying the Fund's accounting policies. It also requires the use of assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 4. Critical accounting estimates and judgements (continued)

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

- **Income taxes**

Significant judgment is required in determining the provision for income taxes. There are transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Fund recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the year in which such determination is made.

### 5. Interest Income

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Cash and cash equivalents	11.968	7.748
Listed debt securities at fair value through profit or loss	93.205	227.945
	<u>105.173</u>	<u>235.693</u>

### 6. Net unrealised change on financial assets at fair value through profit or loss

Net unrealised (losses)/gains on financial assets at fair value through profit or loss is analysed as follows:

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Equity securities	(11.944.963)	2.328.999
Listed open-ended investment funds	-	11.322
Unlisted open-ended investment funds	101.576	75.896
Debt securities	129.039	(300.308)
	<u>(11.714.348)</u>	<u>2.115.909</u>

The net unrealised losses from financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial instrument at the beginning of the reporting period and its carrying amount at the end of the reporting period.

## EASTERNMED FUNDS VCIC PLC

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

#### 7. Net realised change on financial assets at fair value through profit or loss

Net realised gains on financial assets at fair value through profit or loss is analysed as follows:

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Equity securities	854.749	319.892
Listed open-ended investment funds	(10.382)	-
Debt securities	<u>(156.660)</u>	<u>(73.613)</u>
	<u>687.707</u>	<u>246.279</u>

The realised gains on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and its settlement price.

#### 8. Finance costs

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Sundry finance expenses	<u>151</u>	<u>2</u>
	<u>151</u>	<u>2</u>

#### 9. Tax

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Corporation tax - current year	704	5.098
Corporation tax - prior years	434	-
Withholding tax	<u>170.558</u>	<u>77.570</u>
Charge for the year	<u>171.696</u>	<u>82.668</u>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 9. Tax (continued)

The tax on the Fund's results before tax differs from the theoretical amount that would arise using the applicable tax rates as follows:

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
(Decrease)/increase in net assets attributable to holders of investor shares before tax	(8.560.868)	3.691.548
Applicable tax rates	12,50	12,50
Tax calculated at the applicable tax rates	(1.070.109)	461.444
Tax effect of expenses not deductible for tax purposes	1.531.194	51.212
Tax effect of allowances and income not subject to tax	(460.381)	(507.778)
10% additional charge	-	220
Prior year tax	434	-
Withholding tax	170.558	77.570
<b>Tax charge</b>	<b>171.696</b>	<b>82.668</b>

The corporation tax rate is 12,5%.

Under certain conditions interest income may be subject to defense contribution at the rate of 30%. In such cases this interest will be exempt from corporation tax. In certain cases, dividends received from abroad may be subject to defense contribution at the rate of 17%.

### 10. Classification and fair values of financial assets and liabilities

The table below provides a reconciliation of the line items in the Fund's statement of financial position to the categories of financial instruments.

31 December 2018	Mandatorily at fair value €	Loans and receivables €	Total €
Cash and cash equivalents	-	6.695.179	6.695.179
Financial assets at fair value through profit or loss	78.132.877	-	78.132.877
<b>Total</b>	<b>78.132.877</b>	<b>6.695.179</b>	<b>84.828.056</b>
		Other financial liabilities €	Total €
Net assets attributable to holders of investor shares		84.824.617	84.824.617
<b>Total</b>		<b>84.824.617</b>	<b>84.824.617</b>
31 December 2017	Designated at fair value €	Loans and receivables €	Total €
Cash and cash equivalents	-	693.314	693.314
Financial assets at fair value through profit or loss	67.742.900	-	67.742.900
<b>Total</b>	<b>67.742.900</b>	<b>693.314</b>	<b>68.436.214</b>
		Other financial liabilities €	Total €
Net assets attributable to holders of investor shares		68.557.565	68.557.565
<b>Total</b>		<b>68.557.565</b>	<b>68.557.565</b>

## EASTERNMED FUNDS VCIC PLC

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

#### 11. Other receivables

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Other receivables	70.253	180.047
	<u>70.253</u>	<u>180.047</u>

Other receivables include final dividends for equity securities in financial assets at fair value through profit or loss, which were declared during the year with a pay date in 2019. The outstanding declared dividends for the year ended 31 December 2018 totaled €70.253 (2017: €180.047) and are presented in the statement of financial position in other receivables.

The exposure of the Fund to credit risk and impairment losses in relation to trade and other receivables is reported in note 3 of the financial statements.

#### 12. Financial assets at fair value through profit or loss

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Balance at 1 January	67.742.900	31.371.620
Additions	28.962.135	39.593.778
Disposals	(6.857.810)	(5.338.407)
Net fair value losses/(gains)	(11.714.348)	2.115.909
<b>Balance at 31 December</b>	<u><b>78.132.877</b></u>	<u><b>67.742.900</b></u>

Financial assets at fair value through profit or loss are analysed as follows:

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
<b>Financial assets at fair value through profit or loss</b>		
Equity securities	68.926.217	61.731.431
Listed open-ended investment funds	-	986.948
Unlisted open-ended investment funds	4.280.566	2.082.353
Debt securities	4.926.094	2.942.168
	<u><b>78.132.877</b></u>	<u><b>67.742.900</b></u>

The financial assets at fair value through profit or loss are marketable securities and are valued at market value at the close of business on 31 December by reference to Stock Exchange quoted bid prices or over the counter prices. The fair value estimation of the financial assets at fair value through profit or loss is disclosed in note 3.

In the statement of cash flows, financial assets at fair value through profit or loss are presented within the section on operating activities as part of changes in working capital. In the statement of comprehensive income, changes in fair values of financial assets at fair value through profit or loss are recorded in operating income.

The exposure of the Fund to market risk in relation to financial assets is reported in note 3 of the financial statements.

## EASTERNMED FUNDS VCIC PLC

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

#### 13. Cash and cash equivalents

For the purposes of the statement of cash flows, the cash and cash equivalents include the following:

	Easternmed Equities Fund Class A 2018	Easternmed Equities Fund Class A 2017
	€	€
Cash at bank	6.695.179	693.314
	<u>6.695.179</u>	<u>693.314</u>

#### Cash and cash equivalents by currency:

	Easternmed Equities Fund Class A 2018	Easternmed Equities Fund Class A 2017
	€	€
United States Dollars	277.104	5.830
Euro	6.143.701	665.378
British Pounds	212.366	22.012
Norwegian Krone	93	94
Swiss Franc	29.595	-
Canadian Dollars	32.320	-
	<u>6.695.179</u>	<u>693.314</u>

The exposure of the Fund to credit risk and impairment losses in relation to cash and cash equivalents is reported in note 3 of the financial statements.

#### 14. Net assets attributable to holders of investor shares

##### Investor shares

The Fund was set up with authorised share capital of 500.000.000 investor shares, no fractions of a share are recognised and each share represents the same percentage holding in the overall assets. The price of each investor share in the Fund, at the time of incorporation, was set at €100, with euro as reference currency.

The initial issued share capital of the Fund is 2.000 investor shares issued at the price of €100 each.

Investor shares are classified into Class A investor shares and Class B investor shares. The rights and obligations of the two share classes are identical, with the exemption of the subscription, redemption and management fee charge.

The Minimum Holding and Minimum Initial Subscription required for Class A investor shares is €800.000 and the Minimum Additional Subscription required for Class A investor shares is €500.000. The Minimum Holding, Minimum Initial Subscription and Minimum Additional Subscription required for Class B investor shares is €5.000. These minimum initial and additional subscription amounts may be reduced or increased, at the discretion of the Fund, whenever the Fund considers it reasonable or appropriate, taking into consideration the diversification of shareholders and other factors and subject to the provisions for amendment to the instruments of incorporation of the Fund.



## EASTERNMED FUNDS VCIC PLC

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

#### 14. Net assets attributable to holders of investor shares (continued)

	Easternmed Equities Fund Class A 2018 Number of shares	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 Number of shares	Easternmed Equities Fund Class A 2017 €
<b>Issued and fully paid</b>				
Balance at 1 January	574.904	68.557.565	359.442	39.948.685
(Decrease)/increase in net assets attributable to holders of investor shares	-	(8.732.564)	-	3.608.880
Issue of investor shares during the year	207.976	24.999.616	215.462	25.000.000
<b>Balance at 31 December</b>	<b>782.880</b>	<b>84.824.617</b>	<b>574.904</b>	<b>68.557.565</b>

The rights attaching to the investor shares are as follows:

- The shares may be redeemed daily at the net asset value per share of the respective class.
- The shares carry a right to receive notice of, attend and vote at general meetings.
- The holders of investor shares are entitled to receive all dividends declared and paid by the Fund. On winding-up, the holders are entitled to a return of capital based on the net asset value per share of their respective classes and if applicable to the class the subscription, and redemption fee.

#### 15. Other payables

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Accruals	73.076	56.274
Payables to related companies (Note 17.3)	582	-
	<b>73.658</b>	<b>56.274</b>

The exposure of the Fund to liquidity risk in relation to financial instruments is reported in note 3 of the financial statements.

#### 16. Current tax liabilities

	Easternmed Equities Fund Class A 2018 €	Easternmed Equities Fund Class A 2017 €
Corporation tax	34	2.422
	<b>34</b>	<b>2.422</b>

# EASTERNMED FUNDS VCIC PLC

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

### 17. Related party balances and transactions

The related party balances and transactions are as follows:

#### 17.1 Investment manager

The Fund has appointed the Management Company to provide management services pursuant to a management agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the investment manager 0,50% per annum for Class A investor shares and 1% per annum for Class B investor shares of the average net asset value of the Fund for the relevant fiscal year, for managing the Fund. The management fee is computed daily on the daily value of the Fund's net assets and is paid by debiting it from the Fund at the end of each month. The management fee includes fees to enable the Management Company to perform its tasks and functions, or to provide services, irrespective of whether those functions is carried out by the Management Company itself or have been outsourced to third parties.

Management fees for the year ended 31 December 2018 totaled €422.870 (2017: €253.186) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €36.792 (2017: €28.873) and it is included in accruals in other payables.

At 31 December 2018, 10.000 Class A investor shares were held by the investment manager.

#### 17.2 Directors' remuneration

Directors' fees paid during the year ended 31 December 2018 totaled €9.570 (2017: €9.570) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €2.393 (2017: €2.393) and it is included in accruals in other payables. Directors' remuneration consisted of only fixed directors' fees and no other staff costs are paid by the Fund.

#### 17.3 Payables to related parties (Note 15)

<u>Name</u>	<u>Nature of transactions</u>	Easternmed	Easternmed
		Equities Fund Class A 2018	Equities Fund Class A 2017
		€	€
Easternmed Asset Management Services Ltd	Other	582	-
		<u>582</u>	<u>-</u>

The payables to related parties were provided interest free, and there was no specified repayment date.

#### 18. Other key contracts

The Fund has appointed the Administrator to provide administrative services pursuant to an administration agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the administrative agent 0,05% per annum of the average net asset value of the Fund for the relevant fiscal year, with a floor of €12.500 and a ceiling of €50.000 per annum. The administration fee is computed daily on the daily value of the Fund's net assets and is billed at the end of each month. The administration fees for the year ended 31 December 2018 totaled €42.287 (2017: €25.301) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €7.436 (2017: €2.887) and it is included in accruals in other payables.

## **EASTERNMED FUNDS VCIC PLC**

---

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018**

#### **18. Other key contracts (continued)**

The Fund has appointed the Depositary to provide depositary services pursuant to a depositary agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the depositary 0,05% per annum of the average net value of the Fund's assets held by the Depositary during the relevant fiscal year with a minimum fee of €2,500 per quarter. The Depositary's fee is computed daily on the daily valuation of the net assets held by the Depositary and billed at the end of each quarter. This fee includes Depositary fees which may be payable to third parties who undertake to safeguard all or part of the assets of the Fund on the basis of outsourcing arrangements. The depositary fees for the year ended 31 December 2018 totaled €44,067 (2017: €26,427) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €12,081 (2017: €8,641) and it is included in accruals in other payables.

#### **19. Contingent liabilities**

The Fund had no contingent liabilities as at 31 December 2018.

#### **20. Commitments**

The Fund had no capital or other commitments as at 31 December 2018.

#### **21. Events after the reporting period**

There were no material events after the reporting period, which have a bearing on the understanding of the financial statements.

**Independent auditors' report on pages 4 to 6**

## EASTERNMED FUNDS VCIC PLC

### SCHEDULE OF INVESTMENTS - UNAUDITED FOR THE YEAR ENDED 31 DECEMBER 2018

	Easternmed Equities Fund Class A Fair value 2018 €	Easternmed Equities Fund Class A Percentage of Net Assets 2018 %
<b>ASSETS</b>		
<b>Equity securities, listed</b>		
NYSE and European exchange-traded equity securities:		
38.300 shares in Arconic Inc	563.963	0,66%
268.000 shares in Aviva Plc	1.124.993	1,33%
124.500 shares in Axa SA	2.347.821	2,77%
36.600 shares in Baker Hughes a GE Co	687.249	0,81%
20.000 shares in BASF SE	1.208.000	1,42%
170.000 shares in BHP Group Plc	3.138.766	3,70%
6.500 shares in Bayerische Motoren Werke AG	459.550	0,54%
11.000 shares in BNP Paribas SA	434.225	0,51%
150.000 shares in BP Plc	831.638	0,98%
12.000 shares in Capgemini SA	1.041.600	1,23%
25.001 shares in Carrefour SA	372.765	0,44%
5.000 shares in Chevron Corp	475.065	0,56%
46.000 shares in Cie de Saint-Gobain	1.341.590	1,58%
31.000 shares in Citigroup Inc	1.409.485	1,66%
19.000 shares in CRH Plc	438.900	0,52%
31.000 shares in DowDuPont Inc	1.447.930	1,71%
115.000 shares in E.ON SE	992.105	1,17%
120.000 shares in Enel SpA	605.280	0,71%
130.800 shares in Engie SA	1.638.270	1,93%
35.500 shares in Exxon Mobil Corp	2.114.188	2,49%
80.000 shares in Gaslog Ltd	1.150.044	1,36%
12.500 shares in H. Lundbeck A/S	477.750	0,56%
130.000 shares in Iberdrola SA	912.340	1,08%
100.000 shares in ING Groep NV	941.000	1,11%
45.000 shares in LafargeHolcim Ltd (CHF)	1.617.269	1,91%
80.000 shares in LafargeHolcim Ltd	2.866.400	3,38%
1.000.000 shares in Lloyds Banking Group Plc	579.634	0,68%
6.450 shares in Muenchener Rueckversicherungs-Gesellschaft AG	1.229.047	1,45%
15.000 shares in Nestle SA	1.062.206	1,25%
66.000 shares in Noble Corp Plc	151.022	0,18%
24.650 shares in Novartis AG	1.838.305	2,17%
21.550 shares in Novo Nordisk A/S	859.714	1,01%
85.100 shares in Orange SA	1.204.590	1,42%
21.000 shares in Pfizer Inc	800.568	0,94%
120.000 shares in Prudential Plc	1.880.764	2,22%
30.000 shares in Rio Tinto Plc	1.250.936	1,47%
83.404 shares in Royal Boskalis Westminster NV	1.812.369	2,14%
239.000 shares in Royal Dutch Shell Plc	6.131.545	7,23%
30.000 shares in Schlumberger Ltd	945.328	1,11%
15.000 shares in Siemens AG	1.460.700	1,72%
198.807 shares in Suez SA	2.292.245	2,70%
82.000 shares in Suncor Energy Inc	2.003.627	2,36%
158.000 shares in Telefonaktiebolaget LM Ericsson	1.200.546	1,42%
143.000 shares in Total SA	6.603.740	7,79%
100.000 shares in Tsakos Energy Navigation Ltd	232.314	0,27%
60.000 shares in UBS Group AG	651.433	0,77%
8.000 shares in UCB SA	570.400	0,67%

# EASTERNMED FUNDS VCIC PLC

## SCHEDULE OF INVESTMENTS - UNAUDITED FOR THE YEAR ENDED 31 DECEMBER 2018

	Easternmed Equities Fund Class A Fair value 2018 €	Easternmed Equities Fund Class A Percentage of Net Assets 2018 %
<b>ASSETS</b>		
<b>Equity securities, listed(continued)</b>		
NYSE and European exchange-traded equity securities: (continued)		
96.200 shares in Veolia Environment SA	1.727.271	2,04%
350.000 shares in Vodafone Group Plc	598.247	0,71%
7.315 shares in VP Bank AG	917.864	1,08%
95.000 shares in Wallenius Wilhelmsen Logistics	283.616	0,33%
<b>Total equity securities, listed</b>	<b>68.926.217</b>	<b>81,26%</b>
<b>Open-ended investment funds, unlisted</b>		
Unlisted open-ended investment funds:		
58.500 units in BlackRock Global Funds - World Healthscience Fund D2	2.307.812	2,72%
1.160 units in Viopartner SICAV - MIV Global Medtech Fund	1.972.754	2,33%
<b>Total open-ended investment funds, unlisted</b>	<b>4.280.566</b>	<b>5,05%</b>
<b>Debt securities</b>		
NYSE, Asia and European exchange-traded debt securities:		
Credit Suisse AG 5,4% 14/1/2020	907.616	1,07%
Deutsche Bank AG 5% 24/6/2020	743.090	0,88%
Gazprombank 4% 1/7/2019	516.267	0,61%
Hellenic Petroleum Finance Plc 5,25% 4/7/2019	417.368	0,49%
Huarong Finance II 2,875% 22/11/2019	867.087	1,02%
Lukoil International Finance BV 7,25% 5/11/2019	453.715	0,53%
Petroleos Mexicanos 3,125% 27/11/2020	1.020.951	1,20%
<b>Total debt securities</b>	<b>4.926.094</b>	<b>5,81%</b>
<b>Total investments</b>	<b>78.132.877</b>	<b>92,11%</b>
Cash and cash equivalents	6.695.179	7,89%
Other liabilities in excess of other assets	(3.439)	0,00%
<b>Total net assets</b>	<b>84.824.617</b>	<b>100,00%</b>